☆ 4.7 Article

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Biochemical Research Methods

Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment

Yu Wang et al.

Summary: This study developed and validated a method using ultra-performance liquid chromatography-tandem mass spectrometry to simultaneously quantify Contezolid and its metabolite M2 in human plasma and urine. The method was accurate, rapid, and successfully applied to pharmacokinetic research.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2022)

Add to Collection

Article Microbiology

Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections

Hong Yuan et al.

Summary: This study aimed to build a population pharmacokinetic model for contezolid tablet in healthy subjects and adults with complicated skin and soft-tissue infections to evaluate its efficacy and safety. The study found that a dosing regimen of 600 mg or 800 mg every 12 hours is expected to have good clinical and microbiological efficacy against infections caused by S. aureus. The study also showed that the dosing regimen of 800 mg every 12 hours administered postprandially for 7 to 14 days is slightly more effective than that of 600 mg.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Review Infectious Diseases

Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision

Hubert C. Chua et al.

Summary: Antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) principles and models play a crucial role in understanding antibiotic killing mechanisms and optimizing dosing regimens for clinical outcomes. Personalized dosing based on proper pharmacokinetic sampling can enhance efficacy and minimize toxicity, while the development of integrated mechanistic models can further improve individualized dosing regimens.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Add to Collection

Article Infectious Diseases

Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care ?

Tanner M. Johnson et al.

Summary: Complicated methicillin-resistant Staphylococcus aureus bloodstream infections, especially those with delayed culture clearance, have high mortality rates. Combination therapy with daptomycin and ceftaroline (DAP + CPT) shows potential for better outcomes compared to standard of care in treating these infections, with lower rates of clinical failure observed in patients receiving DAP + CPT.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Add to Collection

Article Microbiology

Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development

Xiaojie Wu et al.

Summary: Contezolid (MRX-I), a novel oxazolidinone antibiotic, was approved for treating Gram-positive infections. In a human mass balance study, the pharmacokinetics and disposition of [C-14]contezolid were investigated, revealing a disproportionate amount of metabolites MRX445-1 and MRX459 in human plasma compared to rat or dog samples. Additional nonclinical studies confirmed that the primary metabolite MRX445-1 has no clinically relevant pharmacology and toxicity in humans.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Contezolid: First Approval

Sheridan M. Hoy

Summary: Contezolid, an orally administered oxazolidinone antibacterial agent, has been approved in China for the treatment of complicated skin and soft tissue infections, with a recommended dosage of 800 mg every 12 hours. It is also undergoing clinical development in the USA for acute bacterial skin and skin structure infections and diabetic foot infections.

DRUGS (2021)

Add to Collection

Article Medicine, Research & Experimental

Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment

Eman El-Khateeb et al.

Summary: Liver cirrhosis affects the abundance of drug-metabolizing enzymes and transporters, leading to non-uniform reductions in levels that necessitate the use of PBPK models for precise drug dosing.

MOLECULAR PHARMACEUTICS (2021)

Add to Collection

Article Microbiology

Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers

Junzhen Wu et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients

Li Li et al.

CLINICAL THERAPEUTICS (2020)

Add to Collection

Review Microbiology

Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research

Nicholas A. Turner et al.

NATURE REVIEWS MICROBIOLOGY (2019)

Add to Collection

Article Pharmacology & Pharmacy

Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis

Junzhen Wu et al.

CLINICAL THERAPEUTICS (2019)

Add to Collection

Article Pharmacology & Pharmacy

Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects

Xiaojie Wu et al.

CLINICAL THERAPEUTICS (2018)

Add to Collection

Review Microbiology

Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology

Sahreena Lakhundi et al.

CLINICAL MICROBIOLOGY REVIEWS (2018)

Add to Collection

Article Microbiology

Single-and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects

Paul B. Eckburg et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance

Christoph G. Dietrich et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Article Pharmacology & Pharmacy

Metabolism of MRX-I, a Novel Antibacterial Oxazolidinone, in Humans: The Oxidative Ring Opening of 2,3-Dihydropyridin-4-One Catalyzed by Non-P450 Enzymes

Jian Meng et al.

DRUG METABOLISM AND DISPOSITION (2015)

Add to Collection

Article Microbiology

Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

S. Flanagan et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

Add to Collection

Article Immunology

Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future

Keith A. Rodvold et al.

CLINICAL INFECTIOUS DISEASES (2014)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

Roger K. Verbeeck

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)

Add to Collection

Article Microbiology

Hematologic effects of linezolid: Summary of clinical experience

SL Gerson et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.